文献速递炎症性肠病

托法替布治疗溃疡性结肠炎的疗效与安全性:基于既往TNF抑制剂失败状态的分析

Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status.
PubMed 文献 · Clin Gastroenterol Hepatol · 2021-03-06

该研究汇总了托法替布治疗溃疡性结肠炎的临床试验数据,按既往TNF抑制剂失败状态分层。无论既往是否TNF抑制剂失败,托法替布均优于安慰剂;但既往TNF抑制剂失败者带状疱疹发生率数值上更高。剂量递增至10mg每日两次可重新获得临床应答。

要点

  • 托法替布对溃疡性结肠炎的疗效不受既往TNF抑制剂失败状态影响。
  • 既往TNF抑制剂失败者带状疱疹发生率数值上高于无失败者。
  • 剂量递增至10mg每日两次可重新获得临床应答。

核心结论

  • 托法替布在溃疡性结肠炎患者中有效,无论既往是否TNF抑制剂失败。
  • 既往TNF抑制剂失败的患者带状疱疹(非严重和严重)发生率数值上更高。

研究设计与样本

  • 疗效评估基于汇总的3期OCTAVE诱导1和2研究(N=1139)、3期OCTAVE维持研究(N=593)及开放标签长期扩展OCTAVE Open的剂量递增亚组(N=59)。
  • 安全性评估基于OCTAVE维持研究、剂量递增亚组及总队列(N=1124;无既往TNF抑制剂失败N=541;有既往TNF抑制剂失败N=583)。
  • 剂量递增亚组在OCTAVE诱导1和2接受托法替布10mg每日两次,在OCTAVE维持接受5mg每日两次,在OCTAVE Open接受10mg每日两次。

主要发现

  • 无论既往TNF抑制剂失败状态,托法替布疗效均优于安慰剂。
  • 在OCTAVE维持研究和总队列中,托法替布治疗患者中既往TNF抑制剂失败者带状疱疹(非严重和严重)发生率数值上高于无失败者。
  • 剂量递增至托法替布10mg每日两次通常可使大多数患者重新获得临床应答。
  • 剂量递增亚组带状疱疹(非严重和严重)发生率数值上高于总队列。

关键数值与推荐

  • 疗效数据来自OCTAVE诱导1和2研究(N=1139)。
  • 维持治疗数据来自OCTAVE维持研究(N=593)。
  • 剂量递增亚组样本量N=59,接受托法替布10mg每日两次(OCTAVE Open)。
  • 总队列N=1124,其中无既往TNF抑制剂失败N=541,有既往TNF抑制剂失败N=583。

临床怎么用

  • 对于溃疡性结肠炎患者,无论既往是否TNF抑制剂失败,托法替布均为有效治疗选择。
  • 既往TNF抑制剂失败者使用托法替布时需关注带状疱疹风险。
  • 对托法替布5mg每日两次应答不足者,可考虑剂量递增至10mg每日两次以重新获得应答。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Tofacitinib is an oral, small-molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). We summarize the efficacy and safety data of tofacitinib 5 or 10 mg twice daily in the UC clinical program, stratified by prior tumor necrosis factor inhibitor (TNFi) failure status. METHODS: Efficacy was assessed in the pooled phase 3 OCTAVE Induction 1 and 2 studies (N = 1139), the phase 3 OCTAVE Sustain maintenance study (N = 593), and the dose-escalation subpopulation of the open-label, long-term extension OCTAVE Open study (N = 59). Safety was assessed in OCTAVE Sustain, the dose-escalation subpopulation, and the Overall Cohort, which included patients from OCTAVE Induction 1 and 2, OCTAVE Sustain, and OCTAVE Open (N = 1124; no prior TNFi failure N = 541; prior TNFi failure N = 583; phase 2 data were excluded when stratified by prior TNFi failure status). The dose-escalation subpopulation received tofacitinib 10 mg twice daily in OCTAVE Induction 1 and 2, tofacitinib 5 mg twice daily in OCTAVE Sustain, and tofacitinib 10 mg twice daily in OCTAVE Open. RESULTS: Tofacitinib had greater efficacy than placebo, regardless of prior TNFi failure status. In OCTAVE Sustain and the Overall Cohort, herpes zoster [HZ] (nonserious and serious) rates were numerically higher in tofacitinib-treated patients with vs without prior TNFi failure. Dose escalation to tofacitinib 10 mg twice daily generally recaptured clinical response for most patients. HZ (nonserious and serious) rates were numerically higher in the dose-escalation subpopulation vs the Overall Cohort. CONCLUSIONS: Tofacitinib was efficacious in patients with UC regardless of prior TNFi failure status. HZ (nonserious and serious) rates were numerically higher in patients who had previously failed TNFi. ClinicalTrials.gov: A3921063 (NCT00787202); OCTAVE Induction 1 (NCT01465763); OCTAVE Induction 2 (NCT01458951); OCTAVE Sustain (NCT01458574); and OCTAVE Open (NCT01470612).

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Sandborn WJ, Peyrin-Biroulet L, Sharara AI, et al. Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status. Clin Gastroenterol Hepatol. 2021. PMID: 33684552. doi:10.1016/j.cgh.2021.02.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。